A team with purpose

Leveraging our extensive experience bringing gene therapies to market, our leadership team brings the clinical, manufacturing and commercial know-how needed to accelerate transformational therapeutic programs. Patient safety and well-being are at the center of everything we do, without compromise.

Scroll to Team with purpose

We are mobilizing and accelerating viable success

How we do it… 1 /4

Proven Team with Gene Therapy Expertise

Cross-functional team with a proven track record and hands-on experience expediting gene therapy products from construct to commercialization.

  • Experienced and proven management team
  • Extended team with deep manufacturing, quality, clinical, regulatory, and commercial expertise
  • Scalable GMP development and technical know-how

Operational Excellence

Leveraging our wealth of experience, we anticipate what regulators will require and execute to expedite development timelines. Our proven process minimizes rework, drives down costs, and allows medicines to reach patients safely and quickly.

Innovative Clinical & Regulatory Strategies

Our regulatory strategies and clinical development plans incorporate commercial requirements and insightful preclinical/clinical endpoints to create value and optimize market access and patient reach.

Best-in-Class Gene Therapy CMC Team

We leverage our industry-leading quality and manufacturing teams to rapidly develop and expedite development timelines. The Jaguar CMC team has successfully brought gene therapy products from early stage R&D through commercial launch.

Executive Team

Joe Nolan

Joe Nolan Chief Executive Officer

Joe Nolan LinkeIn Profile

Joe is a results focused pharma growth leader with 30 plus years of experience building high performance teams, driving operational efficiency and growing products in competitive pharma spaces. Accountable for full P&L and revenue generation.

Former AveXis, Lundbeck, and Abbott Laboratories.

Sukumar “Suku” Nagendran, MD

Sukumar “Suku” Nagendran, MD Chief Medical Officer

Sukumar “Suku” Nagendran, MD, MD LinkeIn Profile

Suku brings more than 25 years of experience in gene therapy development, clinical development strategy, medical affairs, diagnostics, payer strategy and commercialization of therapeutic products; also currently advising many other gene therapy and healthcare companies.

Formerly of AveXis, Quest Diagnostics and Pfizer.

Andrew Knudten, MS, MBA

Andrew Knudten, MS, MBA Chief Operating Officer

Andrew Knudten, MS, MBA LinkeIn Profile

With an MS in Cell Biology and Genetics, Andrew leverages his extensive experience in developing and successfully commercializing gene therapy treatments including manufacturing, process development and supply chain know-how.

Formerly of AveXis, Hospira, Novartis, and Amgen.

Phil Donenberg, CPA

Phil Donenberg, CPA Chief Financial Officer

Phil Donenberg LinkeIn Profile

Phil contributes more than 25 years of leadership expertise in finance, mergers and acquisitions and operations in the gene therapy, specialty, pharmaceutical and biotech industries.

Formerly of AveXis, RestorGenex and BioSante Pharmaceutical.

Mike Johannesen

Michael Johannesen Chief Legal Officer

Mike Johannesen LinkeIn Profile

Mike is a pragmatic, outcome-driven leader with 25 years of varied legal experience in the healthcare industry ranging from large branded pharma, generic pharma, med device and gene therapy.

Formerly of AveXis, Hospira and Abbott.

Board of Directors

Sean P. Nolan

Sean P. Nolan Executive Chairman, Jaguar Gene Therapy Board of Directors

Sean brings diverse functional expertise inclusive of commercial operations, global marketing, corporate and business development and global manufacturing and supply chain management.

Sean formerly served as CEO of AveXis.

Joe Nolan

Joe Nolan CEO at Jaguar Gene Therapy

Joe is a results focused pharma growth leader with 30 plus years of experience building high performance teams, driving operational efficiency and growing products in competitive pharma spaces. Accountable for full P&L and revenue generation.

Former AveXis, Lundbeck, and Abbott Laboratories.

Elise Wang

Elise Wang Deerfield Management Company

Ms. Wang provides provides extensive research and analysis on individual companies operating in the healthcare industry in both the US and Europe.

Dave Greenwald, Ph.D.

Dave Greenwald, Ph.D. Deerfield Management Company

David Greenwald, Ph.D., focuses on early-stage biotechnology investments and supports Deerfield private portfolio companies corporate strategy and business development.

Jonathan Leff

Jonathan Leff Deerfield Management Company

Jonathan focuses on venture capital and structured investments in biotechnology and pharmaceuticals.

Dave Fellows

Dave Fellows Former CEO, Nightstar Therapeutics

Dave brings 40 years of experience in the biopharmaceutical industry with global expertise in business development, marketing, and operations. His most recent role was CEO of Nightstar Therapeutics and currently serves on the board of Oxular ltd. and the Glaucoma Foundation.

Dave Greenwald, Ph.D.

Kenneth L. Custer, Ph.D., MBA Eli Lilly and Company

Ken brings his diverse background across the biological sciences, drug development and commercialization. He is passionate about working at the intersection of science, technology and business, and is currently VP and Head of Corporate Business Development and Lilly New Ventures for Eli Lilly and Company.

Defined by collaboration, driven by urgency

We work as one, bringing highly focused collaboration to each of our gene therapy programs – we empower our physician-scientists with the structure and support required to expedite the successful transition from preclinical to clinical models.